Skip to main content
OpenTrials
Completed

NCT Number: NCT05265182

ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia

The proposed research project aims to answer the question "Are immersive technology systems effective in the management and treatment of patients with BPSD?". This project is composed of three phases and the current study is the first phase. The phase 1 trial aims to create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–59 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

College of Allied Medical Professions Clinic for Therapy Services

Manila, National Capital Region, 1000, Philippines

About this study

The participants will undergo an intervention using the assigned ImGTS for four sessions (twice a week for two weeks), with a maximum of 45 minutes per session. VR trials are in 10- to 20-minute periods with introduction, orientation, and provisions for rest periods for patient comfort. During the experience, documentation of the patient's reaction and interaction with the ImGTS will be recorded by the researchers. The participants will be staying at the designated laboratory for not more than one hour.

Demographic characteristics Demographic characteristics of the participant (age, sex, educational attainment, marital status, living conditions, hobbies and interests, previous experience with VE applications, existing illnesses, medications) will be collected by the researchers through a questionnaire. Personal data, such as name and contact information, will only be collected to allow the investigators to contact the participants, as needed.

Safety Safety will be ensured by assessing a participant's experience of cybersickness. A cybersickness questionnaire, the Virtual Reality Sickness Questionnaire will be administered after each session. In this self-report questionnaire, nine symptoms will be rated as absent/none, slight, moderate, or severe. These symptoms are general discomfort, fatigue, eyestrain, difficulty focusing, headache, fullness of head, blurred vision, dizziness when the eyes are closed, and vertigo. Answering the questionnaire will take around 10 minutes.

In the event that a participant will experience severe cybersickness, they may opt to discontinue the experience. They will be instructed to remove the HMD or to step out of the Semi-CAVE room to rest and recover from the symptoms. A medical professional will be present to monitor the participant's symptoms and to attend to them for further management. The reason(s) for discontinuing the experience will be documented.

Acceptability The acceptability of the design will be measured using the Place Probe, a sense of place questionnaire. The questionnaire will be administered after each session, and it will collect information on a participant's experience in the VE application, particularly on (a) their general impression of the environment, (b) the key features of the environment, and (c) their feelings of presence. A positive general impression, a memorable environment, and high level of presence will indicate that the VE developed is acceptable. This will take about 10 minutes to complete.

Usability Usability testing will be performed according to the PNS ISO/IEC Metrics. The goal is to provide continuous improvement in the design and user experience to maximize the three components of usability: effectiveness, efficiency, and satisfaction. Additional usability metrics will be identified during the first phase of the study. The metrics will be specifically adjusted to the target participants as well as the contents to be included in the VR system.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 40 to 59 years old
  • Montreal Cognitive Assessment-Philippine Version (MoCA-P) score > 20
  • Neuropsychiatric Inventory (NPI) score of 0
  • Able to understand Filipino and English

Exclusion criteria

  • Previously diagnosed with dementia
  • Receptive aphasia
  • Previously diagnosed with a psychiatric disorder
  • Previously diagnosed with seizures or epilepsy
  • Significant visual and hearing impairment
  • Has a history of motion sickness
  • Quadriplegia or paralysis of dominant hand
  • Life expectancy of less than a year

Treatment and study plan

Virtual Reality

Procedure

Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.

Primary outcomes

  1. The incidence of cybersickness will be assessed using the Virtual Reality Sickness Questionnaire.

    Time frame: Immediately after each intervention, within an hour of completion of the virtual reality game.

    A 9-item Virtual Reality Sickness Questionnaire to assess cybersickness.

  2. The acceptability of the design will be measured using the Place Probe.

    Time frame: Immediately after each intervention, within an hour of completion of the virtual reality game.

    The Place Probe is a sense of place questionnaire.

  3. The rate of usability will be performed according to the Philippine National Standards ISO/IEC Metrics.

    Time frame: Within an hour of the end of the study.

    The goal is to provide continuous improvement in the design and user experience to maximize the three components of usability: effectiveness, efficiency, and satisfaction.

Sponsors and collaborators

Lead sponsor

Augmented eXperience E-health Laboratory

Other

Registry information

Official study title

Developing an Immersive Gamification Technology System (ImGTS) for the Management of Patients With Behavioral and Psychological Symptoms of Dementia (Phase 1 Trial)

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 3, 2022
Registry last updated
Feb 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.